Drugs for Short Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 71)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ursodeoxycholic acid |
Approved, Investigational |
Phase 4 |
|
128-13-2 |
31401 |
Synonyms:
(3a,5b,7b)-3,7-Dihydroxycholan-24-Oate
(3a,5b,7b)-3,7-Dihydroxy-cholan-24-Oate
(3a,5b,7b)-3,7-Dihydroxycholan-24-Oic acid
(3a,5b,7b)-3,7-Dihydroxy-cholan-24-Oic acid
(3alpha,5beta,7beta)-3,7-Dihydroxycholan-24-Oate
(3alpha,5beta,7beta)-3,7-Dihydroxycholan-24-Oic acid
(3Α,5β,7β)-3,7-dihydroxycholan-24-Oate
(3Α,5β,7β)-3,7-dihydroxycholan-24-Oic acid
(4R)-4-[(1S,2S,5R,7S,9S,10R,11S,14R,15R)-5,9-DIHYDROXY-2,15-DIMETHYLTETRACYCLO[8.7.0.0?,?.0??,??]HEPTADECAN-14-YL]PENTANOIC ACID
3 alpha,7 beta Dihydroxy 5 beta cholan 24 Oic acid
3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-Oic acid
3,7-Dihydroxycholan-24-Oic acid
3a,7b-Dihydroxy-5b-cholan-24-Oate
3a,7b-Dihydroxy-5b-cholan-24-Oic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-Oate
3alpha,7beta-Dihydroxy-5beta-cholan-24-Oic acid
3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid
3-alpha,7-beta-Dihydroxycholanic acid
3-alpha,7-beta-Dioxycholanic acid
3Α,7β-dihydroxy-5β-cholan-24-Oate
3Α,7β-dihydroxy-5β-cholan-24-Oic acid
ACG240
Acid, deoxyursocholic
Acid, ursacholic
Acid, ursodeoxycholic
Acide ursodesoxycholique
Acido ursodeossicolico
Acido ursodeoxicolico
Acidum ursodeoxycholicum
Actigall
Antigall
Antigen brand OF ursodeoxycholic acid
Aventis brand OF ursodeoxycholic acid
Axcan brand OF ursodeoxycholic acid
Cholit-ursan
Cholofalk
CHOLURSO
CP Brand OF ursodeoxycholic acid
Delursan
Deoxyursocholic acid
|
Destolit
Estedi brand OF ursodeoxycholic acid
Falk brand OF ursodeoxycholic acid
Farmasa brand OF ursodeoxycholic acid
Galen brand OF ursodeoxycholic acid
Heumann brand OF ursodeoxycholic acid
Niddapharm brand OF ursodeoxycholic acid
Norgine brand OF ursodeoxycholic acid
NSC-683769
Orphan brand OF ursodeoxycholic acid
Provalis brand OF ursodeoxycholic acid
Sanofi synthelabo brand OF ursodeoxycholic acid
Sodium ursodeoxycholate
Tramedico brand OF ursodeoxycholic acid
UDCA
Urdox
Urosdesoxycholate
Urosdesoxycholic acid
Ursacholic acid
Urso
URSO 250
URSO FORTE
Urso heumann
Ursobilane
Ursochol
Ursodeoxycholate
Ursodeoxycholate, sodium
URSODEOXYCHOLIC ACID
Ursodeoxycholicacid
URSODESOXYCHOLIC ACID
Ursodexycholate
Ursodexycholic acid
Ursodiol
Ursofalk
Ursogal
Ursolite
Ursolvan
Vita brand OF ursodeoxycholic acid
Zambon brand OF ursodeoxycholic acid
|
|
2 |
|
Plasminogen |
Approved |
Phase 4 |
|
9001-91-6 |
|
Synonyms:
1-glutamylplasminogen
Human plasminogen
Plasma trypsinogen
|
plasminogen, human-tvmh
Profibrinolysin
|
|
3 |
|
Carbamide peroxide |
Approved |
Phase 4 |
|
124-43-6 |
|
Synonyms:
Carbamide peroxide
Hydrogen peroxide carbamide
Urea dioxide
|
Urea hydrogen peroxide
Urea peroxide
|
|
4 |
|
Apixaban |
Approved |
Phase 4 |
|
503612-47-3 |
10182969 |
Synonyms:
APIXABAN
APIXABÁN
Apixabanum
BMS 562247-01
|
BMS-562247
BMS-562247|Eliquis®
BMS-562247-01
Eliquis
|
|
5 |
|
Aspartic acid |
Approved, Nutraceutical |
Phase 4 |
|
56-84-8 |
5960 |
Synonyms:
(+)-Aspartate
(+)-Aspartic acid
(+-)-Aspartic acid
(2S)-2-AMINOBUTANEDIOIC ACID
(2S)-2-AMINOSUCCINIC ACID
(2S)-Aspartate
(2S)-Aspartic acid
(L)-Aspartate
(L)-Aspartic acid
(R)-2-Aminosuccinate
(R,S)-Aspartic acid
(S)-(+)-Aspartate
(S)-(+)-Aspartic acid
(S)-2-Aminobutanedioate
(S)-2-Aminobutanedioic acid
(S)-2-Aminosuccinate
(S)-2-Aminosuccinic acid
(S)-Aminobutanedioate
(S)-Amino-butanedioate
(S)-Aminobutanedioic acid
(S)-Amino-butanedioic acid
(S)-Aspartate
(S)-Aspartic acid
[<sup>3</sup>H]-L-aspartate|[<sup>3</sup>H]-L-aspartic acid
2-Amino-3-methylsuccinate
2-Amino-3-methylsuccinic acid
2-Aminosuccinate
2-Aminosuccinic acid
ácido aspártico
Acidum asparticum
alpha-Aminosuccinate
alpha-Aminosuccinic acid
Aminosuccinate
Ammonium aspartate
Asp
Asparagate
Asparagic acid
Asparaginate
Asparaginic acid
Asparatate
ASPARTate
Aspartate magnesium hydrochloride
Aspartate, ammonium
Aspartate, calcium
Aspartate, dipotassium
Aspartate, disodium
Aspartate, magnesium
Aspartate, monopotassium
Aspartate, monosodium
Aspartate, potassium
Aspartate, sodium
|
ASPARTIC ACID
Aspartic acid, ammonium salt
Aspartic acid, calcium salt
Aspartic acid, dipotassium salt
Aspartic acid, disodium salt
Aspartic acid, hydrobromide
Aspartic acid, hydrochloride
Aspartic acid, magnesium (1:1) salt, hydrochloride, trihydrate
Aspartic acid, magnesium (2:1) salt
Aspartic acid, magnesium-potassium (2:1:2) salt
Aspartic acid, monopotassium salt
Aspartic acid, monosodium salt
Aspartic acid, potassium salt
Aspartic acid, sodium salt
Calcium aspartate
D
Dipotassium aspartate
Disodium aspartate
FEMA NO. 3656
H-Asp-OH
Hydrobromide aspartic acid
Hydrochloride aspartic acid
Hydrochloride, aspartate magnesium
L Aspartate
L Aspartic acid
L-(+)-Aspartate
L-(+)-Aspartic acid
L-Aminosuccinate
L-Aminosuccinic acid
L-Asp
L-Asp|L-aspartate
L-Asparagate
L-Asparagic acid
L-Asparaginate
L-Asparaginic acid
L-Asparaginsaeure
L-Asparaginsäure
L-Aspartate
L-Aspartic acid
Magnesiocard
Magnesium aspartate
MG 5 Longoral
MG5Longoral
MG-5-Longoral
Monopotassium aspartate
Monosodium aspartate
NSC-3973
Poly-DL-succinimide
Polysuccinimide
Potassium aspartate
Sodium aspartate
|
|
6 |
|
L-Glutamine |
Approved, Investigational, Nutraceutical |
Phase 4 |
|
56-85-9 |
5961 |
Synonyms:
(2S)-2,5-Diamino-5-oxopentanoate
(2S)-2,5-DIAMINO-5-OXOPENTANOIC ACID
(2S)-2-Amino-4-carbamoylbutanoate
(2S)-2-AMINO-4-CARBAMOYLBUTANOIC ACID
(S)-2,5-Diamino-5-oxopentanoate
(S)-2,5-DIAMINO-5-OXOPENTANOIC ACID
[<sup>14</sup>C]-glutamine
[<sup>3</sup>H]-glutamine
2-Aminoglutaramic acid
Cebrogen
D Glutamine
D-Glutamine
ENDARI
FEMA NO. 3684
gamma-Glutamine
Glavamin
GLN
Glumin
Glutamate 5-amide
Glutamate amide
GLUTAMIC ACID 5-AMIDE
GLUTAMIC ACID AMIDE
Glutamina
GLUTAMINE
L Glutamine
L-(+)-GLUTAMINE
|
L-2-Aminoglutaramate
L-2-AMINOGLUTARAMIC ACID
L-2-Aminoglutaramidic acid
Levoglutamid
Levoglutamida
LEVOGLUTAMIDE
Levoglutamidum
Levoglutamina
L-Glutamate g-amide
L-Glutamate gamma-amide
L-Glutamate γ-amide
L-Glutamic acid 5-amide
L-Glutamic acid g-amide
L-GLUTAMIC ACID GAMMA-AMIDE
L-GLUTAMIC ACID Γ-AMIDE
L-Glutamid
L-Glutamide
L-GLUTAMIN
L-GLUTAMINE
L-GLUTAMINSAEURE-5-AMID
L-GLUTAMINSÄURE-5-AMID
NSC-27421
NUTRESTORE
Polyglutamine
Q
Stimulina
|
|
7 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
8 |
|
bilirubin |
|
Phase 4 |
|
635-65-4 |
5280352 |
Synonyms:
(4Z,15Z)-Bilirubin ixa
(Z,Z)-Bilirubin ixa
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinylbiline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-biline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinylbiline-8,12-dipropionic acid
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-biline-8,12-dipropionic acid
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropanoate
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropanoic acid
2,7,13,17-Tetramethyl-1,19-dioxo-3,18-divinyl-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoate
2,7,13,17-Tetramethyl-1,19-dioxo-3,18-divinyl-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoate
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl)methyl)-4-methyl-5-[(Z)-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
|
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
8,12-Bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbiladiene-ac-1,19(21H,24H)-dione
BILIRUBIN
Bilirubin IX alpha
Bilirubin ixalpha
Bilirubin IX-alpha
Bilirubin(Z,Z)
Bilirubin-ixalpha
Cholerythrin
Hematoidin
NSC-26685
|
|
9 |
|
Tissue Plasminogen Activator |
|
Phase 4 |
|
|
|
10 |
|
N-Methylaspartate |
|
Phase 4 |
|
|
|
11 |
|
Factor Xa Inhibitors |
|
Phase 4 |
|
|
|
12 |
|
Anticoagulants |
|
Phase 4 |
|
|
|
13 |
|
Serine Proteinase Inhibitors |
|
Phase 4 |
|
|
|
14 |
|
Antithrombins |
|
Phase 4 |
|
|
|
15 |
|
Antithrombin III |
|
Phase 4 |
|
|
|
16 |
|
Sitagliptin Phosphate |
|
Phase 4 |
|
654671-77-9 |
|
Synonyms:
JANUMET XR
JANUVIA
MK0431
MK-0431
ONO-5435
|
SITAGLIPTIN MONOPHOSPHATE ANHYDROUS
SITAGLIPTIN MONOPHOSPHATE MONOHYDRATE
SITAGLIPTIN PHOSPHATE
SITAGLIPTIN PHOSPHATE HYDRATE
SITAGLIPTIN PHOSPHATE MONOHYDRATE
|
|
17 |
|
HIV Protease Inhibitors |
|
Phase 4 |
|
|
|
18 |
|
Dipeptidyl-Peptidase IV Inhibitors |
|
Phase 4 |
|
|
|
19 |
|
protease inhibitors |
|
Phase 4 |
|
|
|
Synonyms:
|
20 |
|
D-Alanine |
Experimental, Nutraceutical |
Phase 4 |
|
302-72-7, 338-69-2, 56-41-7 |
101757026 602 71080 5950 |
Synonyms:
(2R)-2-Aminopropanoate
(2R)-2-Aminopropanoic acid
(2R)-2-Aminopropionic acid
(2S)-2-Aminopropanoate
(2S)-2-AMINOPROPANOIC ACID
(a-D-Mannosyl)7-b-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform a (protein)
(R)-2-Aminopropanoate
(R)-2-Aminopropanoic acid
(R)-2-Aminopropionic acid
(R)-Alanine
(S)-(+)-Alanine
(S)-2-Aminopropanoate
(S)-2-Amino-propanoate
(S)-2-Amino-propanoic acid
(S)-2-AMINOPROPANOIC ACID
(S)-ALANINE
(Α-D-mannosyl)7-β-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform a (protein)
[<sup>14</sup>C]-alanine
[<sup>3</sup>H]-alanine
2-Aminopropanoate
2-Aminopropanoic acid
2-Aminopropionate
2-Aminopropionic acid
2-Ammoniopropanoate
2-Ammoniopropanoic acid
A
a-Alanine
a-Aminopropionate
a-Aminopropionic acid
Abufène
ALA
Alanin
Alanina
Alanine
Alanine doms-adrian brand
Alanine, L isomer
Alanine, L-isomer
Alaninum
alpha-Alanine
alpha-Aminopropanoate
alpha-Aminopropanoic acid
alpha-Aminopropionate
|
alpha-Aminopropionic acid
D(-)-a -Alanine
D-(-)-Alanine
D(-)-alpha-Alanine
D(-)-Α-alanine
D-2-Aminopropionate
D-2-Aminopropionic acid
D-a-Alanine
D-a-Aminopropionate
D-a-Aminopropionic acid
DAL
D-Ala
D-Alanin
D-ALANINE
D-alpha-Alanine
D-alpha-Aminopropionate
D-alpha-Aminopropionic acid
Doms adrian brand OF alanine
Doms-adrian brand OF alanine
D-Α-alanine
D-Α-aminopropionate
D-Α-aminopropionic acid
E639
Ellagate arabinoside
L Alanine
L-(+)-Alanine
L-2-Aminopropanoate
L-2-Aminopropanoic acid
L-2-Aminopropionate
L-2-AMINOPROPIONIC ACID
L-a-Alanine
L-a-Aminopropionate
L-a-Aminopropionic acid
L-ALA
L-Alanin
L-Alanine
L-ALPHA-ALANINE
L-alpha-Aminopropionate
L-alpha-Aminopropionic acid
L-Isomer alanine
L-Α-ALANINE
NSC-206315
|
|
21 |
|
Serine |
Investigational, Nutraceutical |
Phase 4 |
|
56-45-1 |
5951 |
Synonyms:
(-)-Serine
(2S)-2-Amino-3-hydroxypropanoate
(2S)-2-Amino-3-hydroxypropanoic acid
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-b,b-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-BETA,BETA-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-β,β-carotene-3,3'-diol
(S)-(-)-Serine
(S)-2-Amino-3-hydroxypropanoate
(S)-2-Amino-3-hydroxy-propanoate
(S)-2-Amino-3-hydroxypropanoic acid
(S)-2-Amino-3-hydroxy-propanoic acid
(S)-a-Amino-b-hydroxypropionate
(S)-a-Amino-b-hydroxypropionic acid
(S)-alpha-Amino-beta-hydroxypropionate
(S)-alpha-Amino-beta-hydroxypropionic acid
(S)-b-Amino-3-hydroxypropionate
(S)-b-Amino-3-hydroxypropionic acid
(S)-beta-Amino-3-hydroxypropionate
(S)-beta-Amino-3-hydroxypropionic acid
(S)-Serine
(S)-Α-amino-β-hydroxypropionate
(S)-Α-amino-β-hydroxypropionic acid
2-Amino-3-hydroxypropanoate
2-Amino-3-hydroxypropanoic acid
3-Hydroxy-L-alanine
|
alpha-Amino-beta-hydroxypropionic acid
beta-Hydroxyalanine
beta-Hydroxy-L-alanine
b-Hydroxyalanine
b-Hydroxy-L-alanine
Bo-xan
e 161b
L Serine
L-(-)-Serine
L-2-Amino-3-hydroxypropionate
L-2-Amino-3-hydroxypropionic acid
L-3-Hydroxy-2-aminopropionate
L-3-Hydroxy-2-aminopropionic acid
L-3-Hydroxy-alanine
L-Ser
L-Serin
L-Serine
S
Ser
Serina
SERINE
Serinum
Xanthophyll
Î’-hydroxyalanine
Î’-hydroxy-L-alanine
|
|
22 |
|
Radiation-Protective Agents |
|
Phase 3 |
|
|
|
23 |
|
Protective Agents |
|
Phase 3 |
|
|
|
24 |
|
Pancrelipase |
Approved, Investigational |
Phase 2 |
|
53608-75-6 |
8519 |
Synonyms:
1,4-ALPHA-D- GLUCAN GLUCANOHYDROLASE
ACCELERASE
COTAZYM
COTAZYM-S
CREON
Endothall
Endothall dipotassium salt
Endothall disodium salt
Endothall disodium salt, (endo,endo)-isomer
Endothall, diammonium salt
ENTOLASE
ILOZYME
KU-ZYME HP
LIPANCREATIN
lipase
|
PA
Pancrealipase
PANCREASE
PANCREATIC ALPHA-AMYLASE PRECURSOR
Pancreatic extract pancrelipase
Pancreatic protease
Pancreatin
Pancreatinum
PANCRELIPASE
Pancrelipase (amylase
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)
protease)
VIOKASE
ZYMASE
|
|
25 |
|
Soybean oil, phospholipid emulsion |
|
Phase 2 |
|
|
|
26 |
|
Pancreatin |
|
Phase 2 |
|
|
|
27 |
|
Mitogens |
|
Phase 2 |
|
|
|
28 |
|
Cola |
|
Phase 2 |
|
|
|
29 |
|
Gastrointestinal Agents |
|
Phase 1, Phase 2 |
|
|
|
30 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
31 |
|
Hypolipidemic Agents |
|
Phase 2 |
|
|
|
32 |
|
Anticholesteremic Agents |
|
Phase 2 |
|
|
|
33 |
|
Lipid Regulating Agents |
|
Phase 2 |
|
|
|
34 |
|
Cholestyramine Resin |
|
Phase 2 |
|
|
|
35 |
|
Amoxicillin |
Approved, Vet_approved |
Phase 1 |
|
26787-78-0 |
33613 |
Synonyms:
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
6-(a-Amino-4-hydroxyphenylacetamido)penicillanic acid
6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin
6-(p-Hydroxy-a-aminophenylacetamido)penicillanate
6-(p-Hydroxy-a-aminophenylacetamido)penicillanic acid
6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanate
6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(p-Hydroxy-α-aminophenylacetamido)penicillanate
6-(p-Hydroxy-α-aminophenylacetamido)penicillanic acid
6-[[Amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9ci
a-Amino-p-hydroxybenzylpenicillin
Actimoxi
Almodan
alpha-Amino-p-hydroxybenzylpenicillin
AMC
Amix
AMIX 125
AMIX 250
AMIX 500
Amoclen
Amolin
Amopen
Amopenixin
Amoram
AMOX
Amox 250 cap 250MG
Amox 500 cap 500MG
Amox S 125 sus 125mg/5ML
Amox S 250 sus 250mg/5ML
Amoxi
Amoxibiotic
Amoxicaps
Amoxicilina
Amoxicilina [INN-Spanish]
Amoxicillin
Amoxicillin (anhydrous)
Amoxicillin and clavulanate potassium
Amoxicillin anhydrous
Amoxicillin clariana brand
AMOXICILLIN HYDRATE
Amoxicillin monopotassium salt
Amoxicillin monosodium salt
Amoxicillin pediatric
Amoxicillin sodium
Amoxicillin trihydrate
Amoxicillin(usan)
Amoxicillin, (r*)-isomer
Amoxicilline
Amoxicilline [INN-French]
Amoxicillinum
Amoxicillinum [INN-Latin]
Amoxid
Amoxiden
AMOXIDENT 250
AMOXIDENT 500
AMOXI-INJECT
Amoxil
AMOXIL FIZTAB
AMOXIL SF
Amoxi-mast
AMOXI-TABS
Amoxivet
Amoxycilin
Amoxycillin
AMOXYCILLIN ANHYDROUS
Amoxycillin trihydrate
Amoxycillin, ban
Amoxymed
AMPC
Amrit
Anemolin
Anhydrous, amoxicillin
Apo-amoxi
Apo-amoxi cap 250MG
Apo-amoxi cap 500MG
Apo-amoxi PWR for susp 125mg/5ML
Apo-amoxi PWR for susp 250mg/5ML
Apo-amoxi sugar free
AQUACIL
Aspenil
AUGMENTIN '125'
AUGMENTIN '200'
AUGMENTIN '250'
AUGMENTIN '400'
AUGMENTIN '500'
|
AUGMENTIN '875'
AUGMENTIN es-600
AX
Biomox
Bristamox
BRL 2333
BRL-2333
Cemoxin
Clamoxyl
Clamoxyl (SKB)
Clamoxyl g.a.
Clamoxyl parenteral
Clariana brand OF amoxicillin
D-(-)-alpha-Amino-p-hydroxybenzyl penicillin
D-(-)-alpha-Amino-p-hydroxybenzylpenicillin
D-(alpha-Amino-p-hydroxybenzyl)penicillin
D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid
D-Amoxicillin
DEDOXIL
Delacillin
Dispermox
Efpenix
Flemoxin
FLEMOXIN SOLUTAB
G.A., clamoxyl
Galenamox
Gen-amoxicillin 250MG
Gen-amoxicillin 500MG
Hiconcil
Histocillin
Hydroxyampicillin
Ibiamox
Imacillin
Lamoxy
Larotid
Metafarma capsules
Metifarma capsules
Moxacin
Moxal
Moxatag
Novamoxin cap 250MG
Novamoxin cap 500MG
Novamoxin sus 125mg/5ML
Novamoxin sus 250mg/5ML
NSC-277174
Nu-amoxi cap 250MG
Nu-amoxi cap 500MG
Nu-amoxi sus 125/5ML
Nu-amoxi sus 250mg/5ML
Ospamox
Pamoxicillin
Parenteral, clamoxyl
Penamox
Pfizer brand OF amoxicillin sodium salt
PHL-Amoxicillin
p-Hydroxyampicillin
Piramox
PMS-Amoxicillin
Polymox
Prevpac
Pro amox PWR for oral susp 125mg/5ML
Pro amox-250 cap 250MG
Pro amox-500 cap 500MG
Pro-amox-250 orl sus 250mg/5ML
RESPILLIN
R-Hydroxyampicillin
Rimoxallin
Robamox
Sauracillin
Sawamox PM
SmithKline beecham brand OF amoxicillin sodium salt
Sodium, amoxicillin
Sumox
Tolodina
Trihydrate, amoxicillin
Trimox
Unicillin
Utimox
Vetramox
VETREMOX
Wymox
Zimox
ZOXYCIL 250
ZOXYCIL 500
Α-amino-p-hydroxybenzylpenicillin
|
|
36 |
|
Levofloxacin |
Approved, Investigational |
Phase 1 |
|
100986-85-4 |
149096 |
Synonyms:
(-)-Ofloxacin
(2S)-7-FLUORO-2-METHYL-6-(4-METHYLPIPERAZIN-1-YL)-10-OXO-4-OXA-1-AZATRICYCLO[7.3.1.0^{5,13}]TRIDECA-5(13),6,8,11-TETRAENE-11-CARBOXYLIC ACID
(3S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylate
(3S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylate
(S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylate
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-Ofloxacin
Anhydrous, levofloxacin
Cravit
DR-3355
EVOXIL
FLOXACIN
Floxin
IQUIX
Levaquin
|
LEVOFLOXACIN
Levofloxacin anhydrous
LEVOFLOXACIN HEMIHYDRATE
Levofloxacin hydrate
Levofloxacine
Levofloxacino
Levofloxacinum
L-Ofloxacin
Ofloxacin
Ofloxacin S-(-)-form
OFLOXACIN S-(-)-FORM HEMIHYDRATE
Ofloxacin, (S)-isomer
OFTAQUIX
QUINSAIR
Quixin
RWJ-25213
TAVANIC
|
|
37 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 1 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
38 |
|
Trimethoprim |
Approved, Vet_approved |
Phase 1 |
|
738-70-5 |
5578 |
Synonyms:
2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
5-[(3,4,5-Trimethoxyphenyl)methyl]-2,4-pyrimidinediamine
BW-5672
BW-56-72
CO-Trimoxazole
IPRAL
LEDATRIM
MONOTRIM
NIH-204
NSC-106568
POLYTRIM
PRIMSOL
Proloprim
PROLOPRIN
|
SYRAPRIM
TCMDC-125538
TIEMPE
TMP
TRIMETHOPRIM
TRIMETHOPRIME
TRIMÉTHOPRIME
TRIMETHOPRIMUM
TRIMETOPRIMA
TRIMOGAL
TRIMOPAN
Trimpex
TRIMPEX 200
TRIPRIMIX 200
|
|
39 |
|
Ofloxacin |
Approved |
Phase 1 |
|
82419-36-1 |
4583 |
Synonyms:
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylate
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
Akilen
Baccidal
Bactocin
Danoflox
DL-8280
Effexin
EXOCIN
Exocine
Flobacin
Flodemex
Flotavid
Flovid
Floxal
Floxil
Floxin
FLOXIN OTIC
Floxstat
Fugacin
Hoe 280
Hoe-280
Inoflox
J01MA01
Kinflocin
Kinoxacin
Liflox
Loxinter
Marfloxacin
Medofloxine
Mergexin
Novecin
Nufafloqo
Obide
Occidal
OCUFLOX
Ofcin
Oflin
Oflocee
Oflocet
|
Oflocin
Oflodal
Oflodex
Oflodura
Oflox
O-Flox
OFLOXACIN
Ofloxacin hydrochloride
Ofloxacine
Ofloxacino
Ofloxacinum
Ofloxin
OFLX
Ofus
Onexacin
Operan
Orocin
Otonil
Pharflox
Praxin
Puiritol
Qinolon
Qipro
Quinolon
Quotavil
Rilox
Sinflo
Tabrin
Taravid
Tariflox
Tarivid
TARIVID 400
TARIVID I.V.
Telbit
Tructum
Uro Tarivid
Viotisone
VISIREN
Zanocin
|
|
40 |
|
Sulfamethoxazole |
Approved |
Phase 1 |
|
723-46-6 |
5329 |
Synonyms:
3-(p-Aminobenzenesulfonamido)-5-methylisoxazole
3-(p-Aminophenylsulfonamido)-5-methylisoxazole
3-(p-Aminophenylsulphonamido)-5-methylisoxazole
3-(Para-aminophenylsulphonamido)-5-methylisoxazole
3-Sulfanilamido-5-methylisoxazole
3-Sulphanilamido-5-methylisoxazole
4-Amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide
4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide
4-Amino-N-(5-methyl-3-isoxazolyl)-benzenesulfonamide
4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulphonamide
5-Methyl-3-sulfanilamidoisoxazole
5-Methyl-3-sulfanylamidoisoxazole
5-Methyl-3-sulfonylamidoisoxazole
5-Methyl-3-sulphanil-amidoisoxazole
ACETYLSULFAMETHOXAZOLE
Apo-Sulfamethoxazole
Azo Gantanol
Azo-gantanol
Bactrim
Bactrimel
Gamazole
Gantanol
GANTANOL (TN)
GANTANOL-DS
Metoxal
N'-(5-methyl-3-isoxazole)sulfanilamide
N'-(5-methyl-3-isoxazolyl)sulfanilamide
N'-(5-methyl-3-isoxazolyl)-sulfanilamide
N'-(5-methylisoxazol-3-yl)sulphanilamide
N^1-(5-methyl-3-isoxazolyl)-sulfanilamide
N1-(5-Methyl-3-isoxazolyl)sulfanilamide
N1-(5-Methyl-3-isoxazolyl)-sulfanilamide
|
N1-(5-Methyl-3-isoxazolyl)sulphanilamide
Ndimethyl1-(5-methyl-3-isoxazolyl)-sulfanilamide
NSC-147832
Radonil
RO-42130
RO-4-2130
Septran
SIM
Simsinomin
Sinomin
SMX
SMZ
STX-608
Sulfamethalazole
Sulfamethoxazol
SULFAMETHOXAZOLE
SULFAMETHOXAZOLE SODIUM
Sulfamethoxazole(usan)
Sulfamethoxizole
Sulfamethylisoxazole
Sulfametoxazol
Sulfisomezole
Sulphamethalazole
Sulphamethoxazol
Sulphamethoxazole
Sulphamethoxazole BP 98
Sulpha-methoxizole
Sulphamethylisoxazole
Sulphisomezole
SUPHAMETHOXAZOLE
Trib
UROBAK
|
|
41 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 1 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
42 |
|
Vaccines |
|
Phase 1 |
|
|
|
43 |
|
Immunologic Factors |
|
Phase 1 |
|
|
|
44 |
|
Antibiotics, Antitubercular |
|
Phase 1 |
|
|
|
45 |
|
Anti-Bacterial Agents |
|
Phase 1 |
|
|
|
46 |
|
Folic Acid Antagonists |
|
Phase 1 |
|
|
|
47 |
|
Folate |
|
Phase 1 |
|
|
|
48 |
|
Vitamin B9 |
|
Phase 1 |
|
|
|
49 |
|
Antiprotozoal Agents |
|
Phase 1 |
|
|
|
50 |
|
Antiparasitic Agents |
|
Phase 1 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 123)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Parenteral Nutrition-associated Cholestasis in Short Bowel Syndrome |
Completed |
NCT01974336 |
Phase 4 |
ursodeoxycholic acid |
2 |
Acute Effects of a Glucagon-like Peptide 2 Analog, Teduglutide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition |
Completed |
NCT02099084 |
Phase 4 |
Teduglutide;Placebo |
3 |
A Monocentric Single-arm Study to Characterize the Long-term Safety, Efficacy, and Pharmacodynamic of GLP-2 Analog (Revestive®) in the Management of Short Bowel Syndrome Pediatric Patients on Home-parenteral Nutrition (HPN) |
Completed |
NCT03562130 |
Phase 4 |
Teduglutide |
4 |
Prophylactic Recombinant Tissue Plasminogen Activator in the Prevention of Central Venous Access Device (CVAD)-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome |
Completed |
NCT02355743 |
Phase 4 |
rtPA lock therapy |
5 |
Influence of Recombinant Human Growth Hormone on Intestinal Permeability and Liver Injury in Intestinal Failure Patients Receiving Parenteral Nutrition (Serono Project) |
Completed |
NCT01380366 |
Phase 4 |
Somatropin |
6 |
Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition |
Recruiting |
NCT04344717 |
Phase 4 |
Apixaban single dose;Apixaban steady-state |
7 |
An Open-label Evaluation of the Long-term Efficacy and Safety of a Standardized Regimen of Growth Hormone, Glutamine and a Modified Diet in the Treatment of Patients With Short Bowel Syndrome |
Terminated |
NCT00742157 |
Phase 4 |
Growth Hormone |
8 |
The Use of Dipeptidyl Peptidase-4 Inhibitor Influences the Absorption of Intestine in Short Bowel Syndrome |
Terminated |
NCT02653131 |
Phase 4 |
Dipeptidyl peptidase-4 inhibitor |
9 |
Safety and Efficacy of SMOFlipid in Patients Intolerant to Intralipid. |
Withdrawn |
NCT03054948 |
Phase 4 |
SMOFLipid;Standard therapy |
10 |
Acute Effects of a Glucagon-like Peptide 1 Analog, Exenatide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition |
Withdrawn |
NCT01818648 |
Phase 4 |
Exenatide;Placebo |
11 |
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support |
Completed |
NCT02682381 |
Phase 3 |
Teduglutide 0.05mg/kg;Teduglutide 0.025 mg/kg |
12 |
A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome |
Completed |
NCT00798967 |
Phase 3 |
teduglutide;placebo |
13 |
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS) |
Completed |
NCT03690206 |
Phase 3 |
glepaglutide;Placebo |
14 |
A 24-week Safety, Efficacy, Pharmacodynamic, and Pharmacokinetic Study of Teduglutide in Japanese Pediatric Subjects, Aged 4 Months Through 15 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support |
Completed |
NCT02980666 |
Phase 3 |
Teduglutide |
15 |
A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support |
Completed |
NCT01952080 |
Phase 3 |
teduglutide |
16 |
A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients With Short Bowel Syndrome Who Completed TED-C14-006 or SHP633-301 |
Completed |
NCT02954458 |
Phase 3 |
TED |
17 |
Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome |
Completed |
NCT00169637 |
Phase 3 |
rhGH |
18 |
A 4-Stage, Open-label, Multicenter Study Including Long-term Extension to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome |
Completed |
NCT02340819 |
Phase 3 |
Teduglutide |
19 |
A Long-Term, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition Dependent Short Bowel Syndrome |
Completed |
NCT00930644 |
Phase 3 |
teduglutide |
20 |
A Randomized, Open-label, 24-Week Safety, Efficacy, and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support |
Completed |
NCT03571516 |
Phase 3 |
Teduglutide |
21 |
A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Japanese Pediatric Subjects With Short Bowel Syndrome Who Completed SHP633-302 |
Completed |
NCT03268811 |
Phase 3 |
Teduglutide |
22 |
A Study of the Safety and Efficacy of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458) |
Completed |
NCT00172185 |
Phase 3 |
teduglutide 0.05 mg/kg/d;teduglutide 0.10 mg/kg/d |
23 |
Fish Oil Lipid Emulsion for the Treatment of Parenteral-Nutrition-Associated Liver Disease in Infants |
Completed |
NCT02370251 |
Phase 2, Phase 3 |
Omegaven |
24 |
A 24-Week Safety, Efficacy, Pharmacokinetic Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Are Dependent on Parenteral Support |
Completed |
NCT03663582 |
Phase 3 |
Teduglutide |
25 |
A Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome |
Completed |
NCT00081458 |
Phase 3 |
Placebo;Teduglutide 0.05 mg/kg/d;Teduglutide 0.1 mg/kg/d |
26 |
Cholestasis Reversal: Efficacy of IV Fish Oil |
Completed |
NCT00910104 |
Phase 2, Phase 3 |
Omegaven® |
27 |
An Open-Label, Extension Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004 |
Completed |
NCT03596164 |
Phase 3 |
Teduglutide |
28 |
A One-Year, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition-dependent Short Bowel Syndrome Who Completed Study CL0600-021 |
Completed |
NCT01560403 |
Phase 3 |
Teduglutide |
29 |
A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed TED-C13-003 |
Completed |
NCT02949362 |
Phase 3 |
Teduglutide |
30 |
A Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Apraglutide in Adult Subjects With Short Bowel Syndrome and Intestinal Failure (SBS-IF) |
Recruiting |
NCT04627025 |
Phase 3 |
apraglutide |
31 |
A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS) |
Recruiting |
NCT03905707 |
Phase 3 |
glepaglutide |
32 |
A Phase 3, Open-label Safety Study of Teduglutide in Japanese Pediatric Patients With Short Bowel Syndrome Who Are Dependent on Parenteral Support, Aged 4 Months of Corrected Gestational Age or Older, and Requiring the Dosing of 1.25 mg Formulation |
Recruiting |
NCT05027308 |
Phase 3 |
Teduglutide |
33 |
An Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. |
Recruiting |
NCT05018286 |
Phase 3 |
Apraglutide |
34 |
A Single-Center Phase 3b Trial Investigating the Long-term Effect on Intestinal Absorption, Nutritional Status and Long-Term Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome (SBS) |
Active, not recruiting |
NCT04991311 |
Phase 3 |
Glepaglutide |
35 |
A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Completing the EASE SBS 2 Trial |
Enrolling by invitation |
NCT04881825 |
Phase 3 |
Glepaglutide |
36 |
Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study |
Terminated |
NCT02266849 |
Phase 3 |
Loperamide;Placebo |
37 |
A Multi-Center, Randomized, Double-Blind, Three-Arm, Parallel-Group Trial to Assess the Efficacy and Safety of NTRA-9620 in Infants With Short Bowel Syndrome (SBS) Following Surgical Resection |
Terminated |
NCT02865122 |
Phase 2, Phase 3 |
NTRA-9620;Placebo |
38 |
A Phase 3, Open Label Extension Study for Subjects That Complete Study MP-101-CL-001 |
Withdrawn |
NCT02246816 |
Phase 3 |
0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) |
39 |
A Phase 3, Open Label Responder Treatment Period With a Randomized, Blinded, Three-Period Crossover, Followed by an Open Label Safety Period to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Investigational Drug MP-101 (Opium Tincture and Opium Tincture With Reduced Uncharacterized Material) to Treat Chronic Diarrhea in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals |
Withdrawn |
NCT02242656 |
Phase 3 |
Opium Tincture USP Deodorized |
40 |
Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants? A Pilot Double Blind Randomized Controlled Trial |
Unknown status |
NCT00793195 |
Phase 2 |
Intralipid 20%;SMOFlipid 20% |
41 |
A Phase I/II Proof of Concept, Open-Label, Repeat Dose, Dose Escalation Study of NM-002 in Adult Patients With Short Bowel Syndrome (SBS) |
Unknown status |
NCT04379856 |
Phase 1, Phase 2 |
NM-002 |
42 |
Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease |
Unknown status |
NCT01739517 |
Phase 2 |
Omegaven Therapy |
43 |
A Phase 2 Trial Testing ZP1848 in Patients With SBS |
Completed |
NCT02690025 |
Phase 2 |
ZP1848 |
44 |
Use of Pancreatic Enzymes in Short Bowel Syndrome |
Completed |
NCT03097029 |
Phase 2 |
Pancreatic Enzyme |
45 |
Diet/Growth Factor Mechanisms of Gut Adaptation |
Completed |
NCT00067860 |
Phase 2 |
recombinant human growth hormone |
46 |
Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies |
Completed |
NCT01674478 |
Phase 2 |
|
47 |
A Once-weekly, Repeated Dose, Placebo Controlled, Double Blind, Randomised Cross-over Trial Investigating Safety, Efficacy and Pharmacodynamics of FE 203799 in Patients With Short Bowel Syndrome With Intestinal Failure Requiring Parenteral Support Followed by an Additional Treatment Period in an Open Label Regimen. |
Completed |
NCT03415594 |
Phase 1, Phase 2 |
FE203799 GLP-2 analogue;FE203799 Placebo GLP-2 analogue |
48 |
A Phase Ib/IIa Open-label, Repeated Dose, Metabolic Balance Study of FE 203799 in Patients With Short Bowel Syndrome and Intestinal Insufficiency |
Completed |
NCT03408132 |
Phase 1, Phase 2 |
FE203799 |
49 |
Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure |
Recruiting |
NCT04604275 |
Phase 2 |
Sucrase |
50 |
A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adult Subjects With Short Bowel Syndrome-associated Intestinal Failure (SBS-IF) |
Recruiting |
NCT04775706 |
Phase 2 |
HM15912 Active;Placebo |
|